Therefore, NAFLD-induced increases in PPARα abundance can be further enhanced by its pharmacological activation: the PPARα agonist WY-14643 protects mice against steatosis and steatohepatitis by preventing intrahepatic lipid and lipoperoxide accumulation [47]. Here, PPARA is linked to steatosis.